Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Aeterna Zentaris currently has license or distribution arrangements in place for macimorelin in the U.S., Canada, Europe,
the UK, and Israel and is actively seeking to expand its relationships for the potential regulatory approval and commercialization of macimorelin in other countries.
Macimorelin is currently marketed in the United States under the tradename Macrilen™ through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. Additionally, upon receipt of pricing and reimbursement approvals in the applicable country, Aeterna Zentaris expects that macimorelin will be marketed in Europe and the United Kingdom through a license agreement with Consilient Health Ltd under which Aeterna Zentaris will receive royalties on sales and other potential payments. In addition, under a commercialization and supply agreement entered into with MegaPharm Ltd., MegaPharm has been granted rights to seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority in exchange for certain royalty and other potential payments to Aeterna Zentaris.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it
for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is also actively pursuing potential business development opportunities for other non-strategic assets to monetize their value.
We are focused on serving the unmet medical needs of patients with rare or orphan endocrine diseases through acquisition, development and licensing of marketed products or development candidates.
Our vision for the future focuses on leveraging our global endocrinology expertise acquired through clinical development of macimorelin in an effort towards establishing a value driven product portfolio for rare and orphan diseases in endocrinology through the potential acquisition of marketed and development-stage medicines and/or in- and out-licensing activities. Our business development team is constantly looking for new opportunities to make strategic deals that have the potential to benefit patients, our partners and our shareholders.
We pledge to act with Integrity — comprising Fairness, Honesty and Perseverance especially when facing difficulties or challenges. In our everyday work, we focus on the following values while upholding the highest ethical standards: Teamwork, Transparency, Innovation, Integrity.